FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000338246> ?p ?o ?g. }

• W2000338246 endingPage "172" @default.
• W2000338246 startingPage "166" @default.
• W2000338246 abstract "Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates cholesterol trafficking by mediating degradation of cell-surface LDL receptors (LDLR). Gain-of-function PCSK9 mutations are known to increase plasma LDL-C levels. We attempted to find gain-of-function PCSK9 mutations in Japanese subjects and determine the frequency and impacts of these mutations, especially on circulating PCSK9 and LDL-C levels.PCR-SSCP followed by direct sequence analysis was performed for all 12 exons and intronic junctions of the PCSK9 in 55 subjects with clinically diagnosed familial hypercholesterolaemia (clinical-FH), who were confirmed to have no LDLR mutations. Among the mutations detected, PCSK9 E32K was likely to be a gain-of-function mutation, and screening was performed by PCR-RFLP in clinical-FH and general Japanese controls. The levels of PCSK9 in plasma from subjects and in media of HepG2 cells transfected with PCSK9 constructs were measured by ELISA.We detected 7 PCSK9 variants, including E32K. The frequency of PCSK9 E32K in clinical-FH (6.42%) was significantly higher than that in controls (1.71%). Three cases representing homozygous FH phenotypes were double heterozygous for PCSK9 E32K and LDLR C183S, C292X or K790X. Two cases were true homozygous for PCSK9 E32K; to our knowledge, these are the first true homozygotes for gain-of-function PCSK9 mutations reported to date. The PCSK9 E32K mutant had over 30% increased levels of PCSK9 in plasma from the subjects and in media of transiently transfected HepG2 cells as compared with those in controls. Furthermore, LDL-C levels in the PCSK9 E32K true homozygotes and heterozygotes were 2.10- and 1.47-fold higher than those in controls with comparable circulating PCSK9 levels, respectively, suggesting enhanced function of PCSK9 E32K.We found 2 true homozygotes for PCSK9 E32K and 3 double heterozygotes for PCSK9 E32K and LDLR mutations associated with autosomal dominant hypercholesterolaemia. This study provided evidence that PCSK9 E32K significantly affects LDL-C levels via increased mass and function of PCSK9, and could exacerbate the clinical phenotypes of patients carrying LDLR mutations." @default.
• W2000338246 created "2016-06-24" @default.
• W2000338246 creator A5001121957 @default.
• W2000338246 creator A5001844280 @default.
• W2000338246 creator A5015289084 @default.
• W2000338246 creator A5060616979 @default.
• W2000338246 creator A5062351415 @default.
• W2000338246 creator A5063363434 @default.
• W2000338246 creator A5075580025 @default.
• W2000338246 creator A5080228002 @default.
• W2000338246 creator A5087125829 @default.
• W2000338246 date "2010-05-01" @default.
• W2000338246 modified "2023-10-12" @default.
• W2000338246 title "The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation" @default.
• W2000338246 cites W1583703772 @default.
• W2000338246 cites W1964279010 @default.
• W2000338246 cites W1982719475 @default.
• W2000338246 cites W1990545107 @default.
• W2000338246 cites W2011511504 @default.
• W2000338246 cites W2012080462 @default.
• W2000338246 cites W2013982259 @default.
• W2000338246 cites W2019173226 @default.
• W2000338246 cites W2031464773 @default.
• W2000338246 cites W2034844930 @default.
• W2000338246 cites W2040612932 @default.
• W2000338246 cites W2045995934 @default.
• W2000338246 cites W2054749768 @default.
• W2000338246 cites W2055571770 @default.
• W2000338246 cites W2067539811 @default.
• W2000338246 cites W2069993714 @default.
• W2000338246 cites W2071154679 @default.
• W2000338246 cites W2078669364 @default.
• W2000338246 cites W2085118290 @default.
• W2000338246 cites W2106759269 @default.
• W2000338246 cites W2112247075 @default.
• W2000338246 cites W2121482887 @default.
• W2000338246 cites W2122864632 @default.
• W2000338246 cites W2141227482 @default.
• W2000338246 cites W2163720603 @default.
• W2000338246 cites W2164103877 @default.
• W2000338246 cites W2166644228 @default.
• W2000338246 cites W2802869499 @default.
• W2000338246 doi "https://doi.org/10.1016/j.atherosclerosis.2009.11.018" @default.
• W2000338246 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20006333" @default.
• W2000338246 hasPublicationYear "2010" @default.
• W2000338246 type Work @default.
• W2000338246 sameAs 2000338246 @default.
• W2000338246 citedByCount "60" @default.
• W2000338246 countsByYear W20003382462012 @default.
• W2000338246 countsByYear W20003382462013 @default.
• W2000338246 countsByYear W20003382462014 @default.
• W2000338246 countsByYear W20003382462015 @default.
• W2000338246 countsByYear W20003382462016 @default.
• W2000338246 countsByYear W20003382462017 @default.
• W2000338246 countsByYear W20003382462018 @default.
• W2000338246 countsByYear W20003382462019 @default.
• W2000338246 countsByYear W20003382462020 @default.
• W2000338246 countsByYear W20003382462021 @default.
• W2000338246 countsByYear W20003382462022 @default.
• W2000338246 countsByYear W20003382462023 @default.
• W2000338246 crossrefType "journal-article" @default.
• W2000338246 hasAuthorship W2000338246A5001121957 @default.
• W2000338246 hasAuthorship W2000338246A5001844280 @default.
• W2000338246 hasAuthorship W2000338246A5015289084 @default.
• W2000338246 hasAuthorship W2000338246A5060616979 @default.
• W2000338246 hasAuthorship W2000338246A5062351415 @default.
• W2000338246 hasAuthorship W2000338246A5063363434 @default.
• W2000338246 hasAuthorship W2000338246A5075580025 @default.
• W2000338246 hasAuthorship W2000338246A5080228002 @default.
• W2000338246 hasAuthorship W2000338246A5087125829 @default.
• W2000338246 hasConcept C104317684 @default.
• W2000338246 hasConcept C126322002 @default.
• W2000338246 hasConcept C134018914 @default.
• W2000338246 hasConcept C2778163477 @default.
• W2000338246 hasConcept C2778824825 @default.
• W2000338246 hasConcept C2778849439 @default.
• W2000338246 hasConcept C2780072125 @default.
• W2000338246 hasConcept C2780948078 @default.
• W2000338246 hasConcept C43554185 @default.
• W2000338246 hasConcept C501734568 @default.
• W2000338246 hasConcept C54355233 @default.
• W2000338246 hasConcept C71924100 @default.
• W2000338246 hasConcept C86803240 @default.
• W2000338246 hasConceptScore W2000338246C104317684 @default.
• W2000338246 hasConceptScore W2000338246C126322002 @default.
• W2000338246 hasConceptScore W2000338246C134018914 @default.
• W2000338246 hasConceptScore W2000338246C2778163477 @default.
• W2000338246 hasConceptScore W2000338246C2778824825 @default.
• W2000338246 hasConceptScore W2000338246C2778849439 @default.
• W2000338246 hasConceptScore W2000338246C2780072125 @default.
• W2000338246 hasConceptScore W2000338246C2780948078 @default.
• W2000338246 hasConceptScore W2000338246C43554185 @default.
• W2000338246 hasConceptScore W2000338246C501734568 @default.
• W2000338246 hasConceptScore W2000338246C54355233 @default.
• W2000338246 hasConceptScore W2000338246C71924100 @default.
• W2000338246 hasConceptScore W2000338246C86803240 @default.
• W2000338246 hasFunder F4320320912 @default.
• W2000338246 hasIssue "1" @default.

• next